The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional ...

Its top-selling treatment, Keytruda, will lose patent protection in a few years. Then Merck will face biosimilar competition and likely see sales slide noticeably. There aren't any obvious ...

We recently made a list of UBS’ Best Stocks In The AI, Growth & Low Rates Era: Top 29 US Stocks. In this piece, we will take ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen, president, Human Health U.S., and Dr. Joerg Koglin, senior vice president and head of ...

We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not ...

MERCK lowered the top end of its full-year sales guidance after demand for its HPV vaccine fell for a second straight quarter ...

Merck, a leading science and technology company, today announced a € 70 million expansion of its ADC manufacturing ...

BusinessWire India Dar es Salaam [Tanzania] Mumbai Maharashtra [India] October 30 Merck Foundation the philanthropic arm of ...

Merck is committed to supporting exceptional biotech companies to both kickstart and streamline their journey from discovery ...

During her keynote speech at the 11th edition of the 'Merck Foundation Africa Asia Luminary,' which was held in Dar es Salaam ...